DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

BLA 125031/S-180

sBLA APPROVAL –
ANIMAL EFFICACY

Amgen Inc.
Attention: Tai H. Yu, M.S.,
Regulatory Affairs
One Amgen Center Drive
Mail Stop 17-2-A
Thousand Oaks, CA 91320-1799

Dear Mr. Yu:

Please refer to your Supplemental Biologics License Application (sBLA), dated February 13, 2015, and received on February 13, 2015, submitted under section 351(a) of the Public Health Service Act for Neulasta® (pegfilgrastim).

We acknowledge receipt of your amendments dated August 14, and 17, 2015.

This Prior Approval supplemental biologics application provides for a new indication of use of Neulasta® (pegfilgrastim) for the treatment of adult and pediatric patients at risk of developing myelosuppression after a radiological/nuclear incident.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, under the provisions of 21 CFR 601, Subpart H (Approval of Biological Products When Human Efficacy Studies Are Not Ethical or Feasible), effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text and required patient labeling. Marketing of this drug product and related activities must adhere to the substance and procedures of the referenced animal efficacy regulations.

SUBPART H APPROVAL REQUIREMENTS

Approvals under 21 CFR Part 601, Subpart H (Approval of Biological Product When Human Efficacy Studies Are Not Ethical or Feasible) are subject to three requirements:

1. *Approval with restrictions to ensure safe use.* This subsection permits the Agency to require postmarketing restrictions as are needed to ensure safe use of the drug product, commensurate with the specific safety concerns presented by the drug product. We have concluded that Neulasta® (pegfilgrastim) can be safely used without restrictions on distribution or use.

2. *Information to be provided to patient recipients.* This subsection requires applicants to prepare labeling to be provided to patient recipients for drug products approved under this subpart. We have concluded that FDA approved patient labeling for Neulasta® (pegfilgrastim) meets the requirement for this subsection. We remind you that the medication guide must be available with the product to be provided, when possible, prior to administration or dispensing of the drug product for the use approved under this subpart.

3. *Postmarketing Studies.* This subsection requires you to conduct postmarketing studies, such as field studies, to verify and describe the biological product's clinical benefit and to assess its safety when used as indicated when such studies are feasible and ethical. We remind you of your postmarketing requirement specified in your protocol outline submission dated December 11, 2014, designed to verify and describe Neulasta (pegfilgastrim)'s clinical benefit and to assess its safety when used as indicated when such studies are feasible and ethical in accordance with 21 CFR 601.90. This requirement, along with required completion dates, is listed below.

   2997-1 Conduct a phase 4 observational study evaluating the efficacy and safety of Neulasta® (pegfilgrastim) in the setting of Hematopoietic Syndrome (HS) following acute radiation exposure.

   Draft Protocol Submission: 05/30/2016
   Final Protocol Submission: 11/30/2016
   Study Completion: To be determined should an event occur
   Final Report Submission: To be determined should an event occur

Submit final reports to this BLA as a supplemental application. For administrative purposes, all submissions relating to this postmarketing requirement must be clearly designated "**Subpart H Postmarketing Requirements**."

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because this drug product for this indication has an orphan drug designation, you are exempt from this requirement.

PROMOTIONAL MATERIALS

Under 21 CFR 601.94, you are required to submit, during the application pre-approval review period, all promotional materials, including promotional labeling and advertisements, that you intend to use in the first 120 days following marketing approval (i.e., your launch campaign). If you have not already met this requirement, you must immediately contact the Office of Prescription Drug Promotion (OPDP) at (301) 796-1200. Please ask to speak to a regulatory project manager or the appropriate reviewer to discuss this issue.

As further required by 21 CFR 601.94, submit all promotional materials that you intend to use after the 120 days following marketing approval (i.e., your post-launch materials) at least 30 days before the intended time of initial dissemination of labeling or initial publication of the advertisement. We ask that each submission include a detailed cover letter together with three copies each of the promotional materials, annotated references, and approved package insert (PI)/Medication Guide/patient PI (as applicable).

Send each submission directly to:

OPDP Regulatory Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotions (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

Alternatively, you may submit promotional materials for accelerated approval products electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, call Frank Lutterodt, Regulatory Project Manager, at (301) 796-4251.

Sincerely,

{See appended electronic signature page}

Libero Marzella, M.D., Ph.D
Director
Division of Medical Imaging Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

LIBERO L MARZELLA
11/13/2015